Company profile
Amyra Biotech AG
AMYRA is developing therapeutic product applications for the treatment of celiac disease and gluten sensitivity, which represent major public health issues. Both conditions are triggered by the ingestion of gluten, which is ubiquitously present in the Western diet and thus almost impossible to avoid.
Source: startup.ch
More news about Amyra Biotech AG
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
